- Home
- QCRH vs FTRE Comparison
QCRH vs FTRE Comparison
Compare QCRH & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QCRH
- FTRE
- Stock Information
- Founded
- QCRH 1993
- FTRE 1996
- Country
- QCRH United States
- FTRE United States
- Employees
- QCRH N/A
- FTRE N/A
- Industry
- QCRH Major Banks
- FTRE Medical Specialities
- Sector
- QCRH Finance
- FTRE Health Care
- Exchange
- QCRH Nasdaq
- FTRE Nasdaq
- Market Cap
- QCRH 1.3B
- FTRE 1.4B
- IPO Year
- QCRH 1993
- FTRE N/A
- Fundamental
- Price
- QCRH $76.58
- FTRE $14.88
- Analyst Decision
- QCRH Buy
- FTRE Hold
- Analyst Count
- QCRH 1
- FTRE 11
- Target Price
- QCRH $82.00
- FTRE $23.30
- AVG Volume (30 Days)
- QCRH 72.8K
- FTRE 1.2M
- Earning Date
- QCRH 01-22-2025
- FTRE 03-03-2025
- Dividend Yield
- QCRH 0.31%
- FTRE N/A
- EPS Growth
- QCRH N/A
- FTRE N/A
- EPS
- QCRH 6.71
- FTRE N/A
- Revenue
- QCRH $330,219,000.00
- FTRE $2,975,600,000.00
- Revenue This Year
- QCRH N/A
- FTRE N/A
- Revenue Next Year
- QCRH $7.47
- FTRE $1.02
- P/E Ratio
- QCRH $11.41
- FTRE N/A
- Revenue Growth
- QCRH N/A
- FTRE 2.80
- 52 Week Low
- QCRH $54.37
- FTRE $14.27
- 52 Week High
- QCRH $96.08
- FTRE $41.02
- Technical
- Relative Strength Index (RSI)
- QCRH 39.20
- FTRE 34.60
- Support Level
- QCRH $75.50
- FTRE $14.88
- Resistance Level
- QCRH $78.68
- FTRE $15.83
- Average True Range (ATR)
- QCRH 1.62
- FTRE 0.69
- MACD
- QCRH 0.08
- FTRE 0.08
- Stochastic Oscillator
- QCRH 36.60
- FTRE 25.85
About QCRH QCR Holdings Inc.
QCR Holdings Inc is a multi-bank holding company. The bank operates through segments namely Commercial Banking, Wealth Management, and all other segments. The commercial bank segment is geographically divided by markets namely QCBT, CRBT, CSB, and GB. It generates revenue in the form of interest.
About FTRE Fortrea Holdings Inc.
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.